3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 2
3
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Uterine Cervical Neoplasms
2
Interventions
Paclitaxel
150
Carboplatin
110
Cisplatin
95
Bevacizumab
42
Topotecan
39
Gemcitabine
38
liposomal doxorubicin
34
Radiotherapy
29
Doxorubicin
27
Brachytherapy
26
Taxes
24
pembrolizumab
20
olaparib
20
Drug Therapy
20
Hyperthermic Intraperitoneal Chemotherapy
16
Chemotherapy, Adjuvant
16
human papillomavirus vaccine, L1 type 16, 18
15
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
Docetaxel
13
Neoadjuvant Therapy
12
Platinum
10
niraparib
9
Radiation
9
1,2-diaminocyclohexaneplatinum II citrate
9
Vaccines, Synthetic
8
Surgical Procedures, Operative
8
atezolizumab
7
Specimen Handling
7
Papillomavirus Vaccines
7
Letrozole
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
tisotumab vedotin
×
Gynecologic
×
Clear all
NCT06459180
2026-05-27
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
686 enrolled
NCT04697628
2026-02-24
innovaTV 301
Seagen Inc.
Phase 3
Completed
502 enrolled
18 charts
1 FDA